MS

Sonendo Announces Inaugural Root Canal Forum for General Dentists

Retrieved on: 
Tuesday, October 17, 2023
General Health, Medical Devices, Health, Dental, Health Technology, NYSE, Root canal treatment, Faculty, MS, BA, Growth, General practice, DDS, Practitioner, Sonia, Dentistry

Sonendo , Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced its first Root Canal Forum for General Dentists, an educational and networking experience created by clinicians, for clinicians aimed at increasing adoption of the GentleWave System.

Key Points: 
  • Sonendo , Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced its first Root Canal Forum for General Dentists, an educational and networking experience created by clinicians, for clinicians aimed at increasing adoption of the GentleWave System.
  • At the forum, attendees will explore innovative avenues to elevate the overall patient experience, impact practice production and develop workflows for root canal therapy.
  • “With an ongoing commitment to empowering and partnering with general practitioners, we are thrilled to host our first-ever Root Canal Forum for General Dentists for current and prospective GentleWave System clinicians,” said Michael Smith, chief commercial officer at Sonendo.
  • For additional information on the Root Canal Forum, visit here .

$10 Million Research Initiative Established to Understand Neuroinflammation's Impact on Broad Range of Brain Diseases

Retrieved on: 
Tuesday, October 17, 2023
Diagnosis, Parkinson's disease, 2018 Chinese Super League, ALS, Schizophrenia, NFLPA, COVID-19, DSM-IV codes, MS, Stroke, NFL, Brain damage, American Academy, Brain, Dementia, Myenteric plexus, The Encephalitis Society, Ageing, Alzheimer's disease, Movement, Nervous system, Encephalitis, National Football League Players Association, American Academy of Neurology, Speech, Immune system, Multiple sclerosis, Infection, Neuroscience, Inflammation, Neuroinflammation, Life, Spectrum, Research, Pharmaceutical industry, Vaccine, Medical device, Neurology

The research initiative is part of the American Brain Foundation's existing Cure One, Cure Many program , which promotes innovative, cross-cutting approaches to brain disease diagnosis and treatment.

Key Points: 
  • The research initiative is part of the American Brain Foundation's existing Cure One, Cure Many program , which promotes innovative, cross-cutting approaches to brain disease diagnosis and treatment.
  • This large-scale, multi-phased initiative will support research to better understand how neuroinflammation acts as an underlying mechanism across nearly all brain diseases and affects people of all ages.
  • "The research funded by the initiative will impact diseases as widespread and different as Parkinson's, encephalitis, multiple sclerosis (MS), Alzheimer's, brain trauma, autism, and others."
  • The American Brain Foundation will begin soliciting research proposals for the neuroinflammation initiative in spring 2024, and research will begin in 2025.

Alquist 3D Appoints Patrick Callahan as New Chief Executive Officer

Retrieved on: 
Tuesday, October 17, 2023
Partnership, Army, COVID-19, MBA, White, MS, Printing, Babson College, Human services, Elaine Alquist, Humanity, Strategic planning, CSI, Mannheimer, Health, Simmons University, QNA, BA, City, White House, Centers for Disease Control and Prevention, Workforce, Growth, Task force, Aims Community College, ADG, Cornell University, Federal Emergency Management Agency, United States Department of Health and Human Services, AirBoss of America, Army Reserve Officers' Training Corps, Sale, ROTC, City Of, Research, United States Department of the Army, Housing, The Global War on Terrorism Memorial Foundation, Management

GREELEY, Colo., Oct. 17, 2023 /PRNewswire-PRWeb/ -- In a planned restructuring, Alquist 3D Founder and current CEO, Zachary Mannheimer, is appointing Patrick Callahan as its new chief executive officer. In addition, Mannheimer is transitioning to chairman of the board. The management restructuring is concurrent with Alquist's relocation from Iowa City, Iowa, to Greeley, Colorado, occasioned by a $4+ million incentive package from the State of Colorado and City of Greeley.

Key Points: 
  • GREELEY, Colo., Oct. 17, 2023 /PRNewswire-PRWeb/ -- In a planned restructuring, Alquist 3D Founder and current CEO, Zachary Mannheimer, is appointing Patrick Callahan as its new chief executive officer.
  • "Patrick is the executive leader we need as we scale up our operations to meet the housing demand.
  • -Zachary Mannheimer, Founder & Board Chairman
    "Patrick is the executive leader we need as we scale up our operations to meet the housing demand," said Mannheimer.
  • For two years prior, Callahan helped lead the company as CSI's chief strategic officer, responsible for CSI's international growth, business development, and research and development operations.

Discovery of Genetic Link to PML Honored by Largest MS Conference in the World

Retrieved on: 
Tuesday, October 17, 2023
Emerald, Dimethyl fumarate, DRS, Best, FAERS, Great America Committee, Cladribine, MS, Research, JC, Abstract, Brain, Biogen, Breast cancer, COVID, Multiple myeloma, Treatment, Daratumumab, Risk, CLIA, Natalizumab, Multiple sclerosis, Discovery, Belimumab, Death, Health, PML, Disease, American Neurological Association, Rheumatoid arthritis, FDA, Database, Gene, Human polyomavirus 2, BRCA, Bone marrow, Black box, Inflammatory bowel disease, Infection, PPV, Ibrutinib, Rituximab, Lupus, Progressive multifocal leukoencephalopathy, HIV/AIDS, Patient, Pharmaceutical industry

NEWPORT BEACH, Calif., Oct. 17, 2023 /PRNewswire/ -- The discovery of rare genomic variants leading to cases of drug-induced PML shared Best of MSMilan2023 honors for the latest and most breakthrough results at the 9th Joint ECTRIMS-ACTRIMS Meeting.

Key Points: 
  • Two of the variants have a Positive Predictive Value of 100%, the strongest possible indication they are causative.
  • Progressive Multifocal Leukoencephalopathy (PML) is a rare but frequently fatal serious infection of the brain by the JC virus.
  • Out of 1,500 abstracts presented, Dr. Hatchwell's was one of eight highlighted as Best of MSMilan2023 in its content area.
  • Many MS medications currently carry a PML warning, including Tysabri, Ocrevus, and Rituxan, as well as Briumvi, Gilenya, Kesimpta, Mavenclad, Mayzent, Ponvory, and Tecfidera.

Verdagy Grows Leadership Team and Announces Rahul Bammi as President

Retrieved on: 
Tuesday, October 17, 2023
Climate, MBA, Climate change, Engineering, MS, United States Department of Energy, National Institute of Technology, Tiruchirappalli, University, Stanford University, Arizona State University, National Semiconductor, VCS, Chemical engineering, Marketing, MOSS, Analysis Group, Motorola, KLA, P&L, IPO, Hydrogen, GTM, Silicon, Management, Renewable energy

MOSS LANDING, Calif., Oct. 17, 2023 /PRNewswire/ -- Verdagy, a pioneer in advanced water electrolysis electrolyzer technologies for large-scale industrial applications, today announced the appointment of Rahul Bammi as President. Rahul reports to CEO Marty Neese and will lead Verdagy's revenue, product management and go-to-market functions including sales, origination, business development, product marketing and corporate marketing.

Key Points: 
  • "Rahul is a terrific and exciting addition to the Verdagy leadership team as we continue to build the industry's leading green hydrogen company.
  • His broad experience growing climate and deep tech companies, and introducing leading-edge products will be invaluable as Verdagy commercializes and scales the deployment of its eDynamic® 20-megawatt electrolyzers," said Marty Neese, Verdagy CEO.
  • I'm thrilled to join Verdagy, and look forward to building an enduring company with Marty and the team that makes a meaningful and positive impact on climate change," said Rahul Bammi, Verdagy President.
  • Bammi joins the company at a pivotal time, as Verdagy recently closed a $73-million Series B funding and announced its Silicon Valley factory .

OneOncology and Practice Partners to Present 11 Abstracts at ASCO Quality Care Symposium

Retrieved on: 
Tuesday, October 17, 2023
DNA sequencing, LPN, MSN, Parent, Workforce, Physician, Comprehensive geriatric assessment, Doctor of Philosophy, Personalized medicine, Abstract, MS, Research, Breast cancer, Economics, Prompt, Palliative care, Community Oncology Alliance, Sibling, Next Generation, Behavior, OCM, DO, FDA, Electronic health record, DNP, Genetic testing, OPN, OCN, Oncology, ASCO, MPT, Occupational therapy, AOCNP, MMHC, The Center, Patient, Quality of life, Vaccine, Pharmaceutical industry, Nursing, Medical imaging, NP-C, MD, Cancer, RN, Germline

NASHVILLE, Tenn., Oct. 17, 2023 /PRNewswire/ -- OneOncology, the national platform for independent oncology practices, announced today that researchers at OneOncology and its partner practices will present 11 abstracts at the upcoming ASCO Quality Care Symposium October 27-28.

Key Points: 
  • Researchers to Present on Genetic Testing, Precision Medicine, Care Delivery & Physician Workforce Research
    NASHVILLE, Tenn., Oct. 17, 2023 /PRNewswire/ -- OneOncology, the national platform for independent oncology practices, announced today that researchers at OneOncology and its partner practices will present 11 abstracts at the upcoming ASCO Quality Care Symposium October 27-28.
  • Neha Jain, Ph.D., OneOncology's Senior Director of Precision Medicine, will present "Provider Messaging for Precision Treatment (ProMPT): A Notification Pilot to Inform Actionable Genomic Findings."
  • The next iteration of ProMPT will use OneOncology's proprietary analytics platform to incorporate genomic information into our physicians' workstream.
  • Tennessee Oncology researchers will present six abstracts addressing topics including clinical innovation, care delivery, OCM learnings and implications for value-based care, automating behavior economics and analytics to improve palliative care, and scaling oncology disease expertise in urban and rural clinics.

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Retrieved on: 
Monday, October 16, 2023
RA, MS, Tendon, B cell, Central nervous system, Therapy, University, Joint, UMB, Rheumatoid arthritis, SILO, Multiple sclerosis, DSM-IV codes, CNS, University of Maryland, College Park, Medical imaging, Fine chemical

ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons. SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).

Key Points: 
  • SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA).
  • “The purpose of this study was to expand our investigation of our patented SPU-21 cyclic peptide beyond preclinical animal models to human tissue assays,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “The data shows strong binding affinity to the main stromal cells in human RA synovial tissue, indicating the peptides’ preferential interaction with the inflamed synovial tissue for disease-suppressive effects.
  • In addition to SPU-21, Silo Pharma holds a license agreement with UMB for a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS) and other rare neurological diseases designated.

Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab

Retrieved on: 
Monday, October 16, 2023
MS, Inflammation, Brain, Central nervous system, Expanded Disability Status Scale, Mass, Hospital, EA, Special access program, Neurology, Harvard Medical School, DSM-IV codes, Patient, HMS, Nursing, Pharmaceutical industry, Brigham, MFIS, Fatigue

It is a major, common, and often debilitating symptom experienced by many individuals with MS.

Key Points: 
  • It is a major, common, and often debilitating symptom experienced by many individuals with MS.
  • It differs from the typical tiredness that everyone experiences from time to time.
  • In the context of MS, it is called ‘primary fatigue’ and is a direct result of damage to the central nervous system.
  • Based on the totality of the clinical results seen to-date, I am hopeful that intranasal foralumab and its anti-inflammatory mechanism of action could provide relief to na-SPMS patients that currently have no available therapies.”

JOY BAUER, MS, RDN + NBC’S TODAY NUTRITION & HEALTHY LIFESTYLE EXPERT TO DELIVER KEYNOTE AT NEW YORK PLASTIC SURGICAL GROUP’S 11TH ANNUAL BREAST CANCER SUMMIT, AIMING TO EMPOWER PATIENTS + CAREGIVERS WITH NUTRITION

Retrieved on: 
Monday, October 16, 2023
Partnership, Knowledge, FACS, Neurosurgery, Diet, MS, Breast cancer, Human, Cardiology, Summit, CDN, Joy Bauer, Cancer, Education, RDN, Speech, Bauer, Survivor, Habit, Patient, Risk, Nursing, MD

The Summit acts as a stage for the most sought-after clinical, industry, and hospital leaders in the tri-state area to share their knowledge and expertise with the upwards of 500 local medical professionals and attendees who are affected by breast cancer in one way or another -- whether personal, a family member or a friend -- in an effort to provide support, awareness and education; the topics for this year’s programming include: new therapies for advanced breast cancer, risk factors that affect cancer, breast reconstruction options, and pre-and post-mastectomy physical therapy.

Key Points: 
  • Garden City, NY, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The upcoming 11th annual Breast Cancer Summit , a complimentary community service event provided by New York Plastic Surgical Group (NYPS Group), the largest and longest-running private academic plastic surgery group in the U.S., is designed around a key topic that drew massive interest in 2022: empowering patients through diet, nutrition and healthy lifestyles.
  • “Every year following the Summit we conduct a post-event survey,” begins Dr. Tommaso Addona, MD, FACS.
  • , breast cancer reconstruction specialist and president of New York Plastic Surgical Group.
  • Today, Bauer is widely recognized as the most trustworthy voice on food science throughout mainstream media.

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

Retrieved on: 
Sunday, October 15, 2023
III, PPT, Pain, Professor, Hidradenitis, Quality of life, European Academies' Science Advisory Council, Pharmacokinetics, Doctor of Philosophy, MS, Journal of the European Academy of Dermatology and Venereology, Education, DLQI, Data, Venereology, Safety, Psoriasis, Hidradenitis suppurativa, Moonlake, Disease, FDA, Adalimumab, Webcast, Immunology, Maintenance, Abscess, I&I, Master of Education, MIRA, PGI, Pennsylvania State University, Patient, HS, Pharmaceutical industry, Perfume, Birth control, Dermatology, MD, Inflammation

We have consistently observed best-in-class clinical activity with our Nanobody®sonelokimab for hidradenitis suppurativa and these results demonstrate its effect on a number of clinically meaningful endpoints.

Key Points: 
  • We have consistently observed best-in-class clinical activity with our Nanobody®sonelokimab for hidradenitis suppurativa and these results demonstrate its effect on a number of clinically meaningful endpoints.
  • In June we elevated the bar for clinical response to HiSCR75 as the primary endpoint.
  • The MIRA trial set a landmark milestone as the first placebo-controlled randomized trial in HS to use Hidradenitis Suppurative Clinical Response 75 (HiSCR75) as the primary endpoint.
  • The 24-week results show that ongoing treatment with sonelokimab 120mg and 240mg dosed Q4W, further increased HiSCR75 response rates compared to week 12.